Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — Investor Presentation (October 2018)
23 slides from Elixinol Wellness's investor presentation, Oct 31, 2018
Slide 1: Wholesale Investor – Sydney Investor Showcase
For personal use only Elixinol Global Limited Wholesale Investor – Sydney Investor Showcase October 2018 DRAFT ASX: EXL, OTCQX: ELLXF | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains summary information about Elixinol Group Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuou
Slide 3: Our products
Our products For personal use only ** * Elixinol is a supplier of bulk CBD to the Pet Releaf range of products as well as providing private label finished goods production services and is also a distributor Page 3 of Pet Releaf Company Presentation products. February 2018
Slide 4: For personal use only
For personal use only Page 4 Company Presentation February 2018
Slide 5: Board and management team and market data
Board and management team and market data For personal use only A senior team, experienced in complex regulatory operating environments Board and management team Elixinol Global market data Andrew Duff | Non-Executive Chairman (ASX: EXL; OTCQX: ELLXF) Experienced ASX listed company director. Ex CFO
Slide 6: Diversified portfolio
Diversified portfolio For personal use only 1H FY2018 revenue by business unit Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medicinal Cannabis Revenue $12.54m (84%) Revenue $2.34m (16%) Seeking licence and permit Submitted licence applications for cultivation and manufacture to Au
Slide 7: Investment highlights
Investment highlights • Elixinol Global (ASX: EXL) listed in January 2018 with strong institutional support For personal use only • EXL is a diversified business with two established consumer product brands in fast growing markets: • Elixinol – US based seller of cannabidiol-based dietary supplement
Slide 8: Diversified across three rapidly growing markets
Diversified across three rapidly growing markets For personal use only Businesses positioned within major growth themes Hemp derived CBD – US market Hemp derived foods – global market Medicinal cannabis – Australian size and projections size and projections+ market projections Developing multi-billi
Slide 9: Hemp and cannabis – rapidly evolving landscape
Hemp and cannabis – rapidly evolving landscape A tide of change is sweeping through hemp and cannabis industries, led by global governments For personal use only 2018 onwards Hemp industry awaits 2014 2014 US Farm Bill signing Agricultural Act of Elixinol starts 2017 2014 (Farm Bill) trading in the
Slide 10: Key financial highlights for 1H FY2018
Key financial highlights for 1H FY2018 1 Revenue 1H FY2018 $14.9m vs 1H FY2017 $7.1m, 110% growth For personal use only H1 FY18 – EXL isUnderlying positioned for strong, EBITDA continued growth 1H FY2018 $0.8m vs 1H FY2017 ($0.1)m loss Group results 1H FY2018 Underlying NPAT 1H FY2018 $0.6m vs 1H FY
Slide 11: Strong growth trajectory across key metrics
Strong growth trajectory across key metrics For personal use only EXL has maintained a strong growth trajectory and delivered a maiden profit in 1H FY2018 Revenue Underlying EBITDA ($m) A$ million, 31 December year end 1H A$ million, 31 December year end 1H 16.5 2H 2H 9.4 0.8 14.9 110% 7.1 0.02 0.10
Slide 12: 3Q FY2018 revenue growth
3Q FY2018 revenue growth* For personal use only Sustained revenue growth to $10.4m – 159% PCP, 27% on 2Q FY2018 Elixinol USA Hemp Foods Australia (hemp-derived CBD dietary supplements) (hemp-derived foods and skincare) • Demand for hemp-derived cannabidiol (CBD) dietary • Strong sales in Hemp Seed O
Slide 13: Revenue growth by consumer products segment
Revenue growth by consumer products segment For personal use only Growth across all revenue segments with a clear strategy to drive higher margin products Elixinol USA Hemp Foods Australia A$ million, 31 December year end 1H FY2017 A$ million, 31 December year end 1H FY2017 1H FY2018 1H FY2018 5.0 2
Slide 14: Elixinol Global 1H FY2018 growth initiatives
Elixinol Global 1H FY2018 growth initiatives For personal use only Disciplined approach to drive future growth • Investment in farming and production capabilities to facilitate future growth • Key sales hires focused on retail distribution which is higher margin • Continued focus on core products an
Slide 15: Elixinol Global international footprint
Elixinol Global international footprint For personal use only An established platform that can be leveraged for consumer products Global platform for growth • Avenues to market established in 40 countries with mix of direct sales and via distribution partners • Facilities (pins) in: • Sydney and Ban
Slide 16: Elixinol USA: positioned for future growth
Elixinol USA: positioned for future growth For personal use only Increased capacity and product development to drive earnings and margin improvement • Elixinol USA is relocating to a new facility in Colorado, USA, designed to be GMP certified and will more than double the usable capacity for process
Slide 17: Elixinol USA: focus for next months
Elixinol USA: focus for next 12 months For personal use only Focus on strong growth in home markets, new product development and marketing • Grow market share in US; deliver growth in attractive markets (Europe, Asia) • Scale teams to support expanded business • Deploy and optimize new US-based plan
Slide 18: Hemp Foods Australia: industry leader
Hemp Foods Australia: industry leader For personal use only Focus on growth of core products and new product offerings • Core product range includes hemp oils, flours, seeds, protein • currently sold via e-commerce and health food shops • Hemp Foods Australia supplying to major FMCG brands including
Slide 19: Hemp Foods Australia: focus for next months
Hemp Foods Australia: focus for next 12 months For personal use only Strong growth in Australia, driving raw and finished product sales via multi-channel approach • Grow Australian market share and secure top 1 position for hemp food branded products • Select Hemp Foods Australia owned brands to be
Slide 20: Elixinol Australia (medicinal cannabis)
Elixinol Australia (medicinal cannabis) For personal use only Advanced development plans are prepared • Strategy to enter Australian medicinal cannabis market and develop export capability • Submitted licence applications for cultivation and manufacture to the Office of Drug Control (ODC) in Awaitin
Slide 21: A race to the bottom or the top?
A race to the bottom or the top? For personal use only DRAFT • Cannabis flowers may become a commodity • Branded products secure loyal customers Page 21 Page 21
Slide 22: Strategic outlook: delivering on our corporate strategy
Strategic outlook: delivering on our corporate strategy For personal use only Capturing substantial global growth opportunity in hemp-CBD and medicinal cannabis FY2021 FY2020 • Global top 3 leadership position in CBD FY2019 • Globally diversified, vertically integrated CBD consumer products consumer
Slide 23: For more information
For personal use only For more information: Paul Benhaim Ron Dufficy Chief Executive Officer Chief Financial Officer DRAFT paul@elixinolglobal.com ron.dufficy@elixinolglobal.com +61 407 767 709 +61 428 881 718
Elixinol Global — Investor Presentation (October 2018) on 6ix